• By ICR Secretariat
  • Posted Thursday, August 26, 2021

EC nod for Astellas, FibroGen’s roxadustat for chronic kidney disease

http://www.pharmatimes.com/news/ec_nod_for_astellas,_fibrogens_roxadustat_for_chronic_kidney_disease_1375485

The European Commission (EC) has approved Evrenzo (roxadustat) for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).